Core Viewpoint - Jingtai Holdings (02228) experienced a significant increase in stock price, opening 15% higher and reaching HKD 7.59 with a trading volume of HKD 1.66 billion, following a major partnership announcement in the AI pharmaceutical sector [1] Group 1: Partnership Details - On August 5, Jingtai Technology announced the completion of a pipeline cooperation agreement with DoveTree, with a total order scale of approximately HKD 470 billion (USD 59.9 billion), marking one of the largest business development transactions in China's AI pharmaceutical field by 2025 [1] - DoveTree has obtained global exclusive development and commercialization rights for the cooperative products, while Jingtai is responsible for utilizing its "AI + robotics" end-to-end platform to develop small molecules and antibody drugs targeting oncology, autoimmune diseases, neurological disorders, and metabolic disorders [1] Group 2: Financial Terms - Jingtai Technology has received an initial payment of USD 51 million as stipulated in the final agreement [1] - Under the terms of the final agreement, Jingtai is entitled to receive an additional payment of USD 49 million (to be paid within 180 days) and is eligible for potential regulatory and commercial milestone payments amounting to USD 5.89 billion, as well as potential single-digit percentage royalties based on annual net sales of the products [1]
晶泰控股高开15% 与DoveTree签订管线合作协议 总订单规模约470亿港元